A gripping look at the rise of the microchip and the British tech company caught in the middle of the global battle for dominance.

One tiny device lies at the heart of the world's relentless technological advance: the microchip. Today, these slivers of silicon are essential to running just about any machine, from household devices and factory production lines to smartphones and cutting-edge weaponry. At the centre of billions of these chips is a blueprint created and nurtured by a single company: Arm.

Founded in Cambridge in 1990, Arm's designs have been used an astonishing 250 billion times and counting. The UK's high-tech crown jewel is an indispensable part of a global supply chain driven by American brains and Asian manufacturing brawn that has become the source of rising geopolitical tension.

With exclusive interviews and exhaustive research, The Everything Blueprint tells the story of Arm, from humble beginnings to its pivotal role in the mobile phone revolution and now supplying data centres, cars and the supercomputers that harness artificial intelligence.

It explores the company's enduring relationship with Apple and numerous other tech titans, plus its multi-billion-pound sale to the one-time richest man in the world, Japan's Masayoshi Son.

The Everything Blueprint details the titanic power struggle for control of the microchip, through the eyes of a unique British enterprise that has found itself in the middle of that battle.

Applications of Nanotechnology in Cancer Chemotherapy offers a complete and concise summary of nanotechnological interventions for cancer management. It highlights the basics of oncology, the cancer microenvironment, targets for active drug delivery, the underlying mechanisms and molecular pathways to enhance the drug delivery to the cancer site. The book discusses the principles of basic and innovative nanocarrier-based therapeutic approaches to modulate the progression of the disease. In addition, this book also explores the evolving targeting approaches specific to the cancer site and type. The scope of the book is not limited to targeted drug delivery for various cancers, but also explores the advancements in cancer imaging and diagnostics employing the nanotechnological tools. Emphasis has been given on the important evaluation techniques like in-vitro cell culture and in-vivo animal models to assess the performance of cancer nanomedicines. The book includes clinical study reports of various drug moieties explored using variety of nanoconstructs in myriad cancer conditions with the input of global market and pharmacoeconomics.